Synergistically improving T-cell responsiveness is promising for favorable therapeutic
outcomes in immunologically cold tumors, yet current treatments often fail to induce a …

The goal of cancer immunotherapy is to clear tumor cells by activating antitumor immunity,
especially by mobilizing tumor-reactive CD8+ T cells. Pyroptosis, programmed lytic cell …

The impressive success of current cancer immunotherapy in some patients but lack of
effectiveness in most patients suggests that additional strategies to promote antitumor …

Pyroptosis is a proinflammatory form of programmed cell death that results in the release of
cellular contents and activation of immune responses. However, GSDME (a pyroptosis …

Pyroptosis-based nanomedicine shows great potential to unchoke the bottlenecks of cancer
immunotherapy, but hindered by precise and specific regulation of pyroptosis in tumor cells …

Pyroptosis refers to the process of gasdermin (GSDM)‐mediated programmed cell death
(PCD). Our understanding of pyroptosis has expanded beyond cells and is known to involve …

Pyroptosis is a necrotic form of regulated cell death. Gasdermines (GSDMs) are a family of
intracellular proteins that execute pyroptosis. While GSDMs are expressed as inactive forms …

Pyroptosis is a gasdermin-mediated programmed necrosis that occurs via membrane
perforation and that can be exploited for biomedical applications in cancer therapy …

Pyroptosis is a newly discovered inflammatory form of programmed cell death, which
promotes systemic immune response in cancer immunotherapy. GSDMD is one of the key …

The immune checkpoint blockade (ICB) antibody immunotherapy has demonstrated clinical
benefits for multiple cancers. However, the efficacy of immunotherapy in tumors is …